Currently, dapagliflozin, a sodium–glucose cotransporter 2 inhibitor (SGLT2i), is recognized as a novel treatment for both type 1 and type 2 diabetes, and is used as an additional therapy to insulin to improve glycemic control and prevent complications of diabetes. This evidence concerns the gene INS and diabetes mellitus.